Healthcare's Quiet Outperformance: How Biotech Earnings Are Defying the Tech Rout

Healthcare Sector Shines as Tech Falters

While Technology, Communication Services, and Healthcare sectors tumbled 2.2%, 1.6%, and 1% respectively on Wednesday, a closer look at midday trading reveals healthcare is quietly outperforming broader market expectations. Amgen Inc. saw its shares jump 8.2% after reporting adjusted earnings of $5.29 per share for the fourth quarter of 2025, significantly beating the Zacks Consensus Estimate of $4.76 per share. This performance stands in sharp contrast to the tech sector's ongoing malaise.

Earnings Drive Selective Strength

Alphabet projected continued heavy spending on artificial intelligence projects, forecasting another $175 billion to $185 billion this year, which spooked investors and triggered a 3% drop in the search giant's stock. Yet the healthcare sector is demonstrating resilience through fundamental strength. Estee Lauder fell more than 11% in pre-bell trading, having topped Wall Street targets but expecting tariff-related headwinds to wipe out approximately $100 million in profits in 2026, showing that even beaten expectations can't overcome macro headwinds in certain sectors.

The Rotation Accelerates

The Energy Select Sector SPDR, Materials Select Sector SPDR, Consumer Staples Select Sector SPDR, and Utilities Select Sector SPDR saw gains of 3.2%, 2.1%, 1.6%, and 1.5%, respectively. Healthcare's modest 1% decline masks significant divergence within the sector, where large-cap pharma and specialty biotech are outperforming. This shift underscores ongoing concerns about the significantly overstretched valuation of technology stocks, especially artificial intelligence (AI)-centric stocks.

What's Driving Healthcare?

The sector benefits from three tailwinds: (1) reasonable valuations compared to mega-cap tech, (2) visible earnings growth from established franchises, and (3) M&A momentum in biopharma. GSK agreed to acquire RAPT Therapeutics in an all-cash transaction that values the company at about $2.2 billion, with an upfront investment of roughly $1.9 billion net of cash, expected to close in the first quarter of 2026. Strategic acquisitions are unlocking value in smaller biotech names.

The Midday Inflection

As investors digest earnings and reassess sector valuations, healthcare's defensive characteristics and earnings visibility are attracting capital fleeing overvalued growth names. Biggest rises came from Merck and Travelers Companies, suggesting rotation toward established, dividend-paying healthcare names. With the employment report due Friday and macro uncertainty elevated, healthcare's combination of earnings strength and lower volatility is becoming increasingly attractive.

Investment Takeaway

While the headline narrative focuses on tech's valuation reset, healthcare's quiet outperformance offers a compelling alternative for investors seeking earnings-driven growth without the AI capex overhang. The sector's M&A pipeline and clinical catalysts provide multiple paths to value creation in 2026.